Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Zhu, Yi ^a,b   Huang, Jian Ming ^a   Zhang, Guo Nan ^a   Zha, Xiao ^a   Deng, Bi Fang ^a  

^a SICHUAN CANCER HOSPITAL   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Metastasis; Myeloid differentiation factor 88; Ovarian cancer; Prognostic factors; Toll like receptor 4

Indexed keywords

MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4;

ADULT; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER PROGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVARY CYST; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOLL-LIKE RECEPTOR 4;

EID: 84862180680     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-77     Document Type: Article

References (31)

1. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res 2003, 9:20-30.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
3. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007, 6:609-621. 10.1517/14740338.6.5.609, 17877447.
4. Schwartz PE. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 2002, 107:99-118.
5. Davidson B, Reich R, Trope CG, Wang TL, Shih Ie M. New determinates of disease progression and outcome in metastatic ovarian carcinoma. Histol Histopathol 2010, 25:1591-1609.
6. Anderson KV, Bokla L, Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 1985, 42:791-798. 10.1016/0092-8674(85)90275-2, 3931919.
7. Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. Science 2002, 296:298-300. 10.1126/science.1068883, 11951031.
8. Akira S. Toll-like receptor signaling. J Biol Chem 2003, 278:38105-38108. 10.1074/jbc.R300028200, 12893815.
9. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004, 431:405-406. 10.1038/431405a, 15385993.
10. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127. 10.1126/science.1140488, 17615359.
11. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, Smyth MJ. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci U S A 2008, 105:652-656. 10.1073/pnas.0708594105, 2206591, 18178624.
12. Coste I, Le Corf K, Kfoury A, Hmitou I, Druillennec S, Hainaut P, Eychene A, Lebecque S, Renno T. Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest 2010, 120:3663-3667. 10.1172/JCI42771, 2947228, 20941850.
13. Byrd-Leifer CA, Block EF, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur J Immunol 2001, 31:2448-2457. 10.1002/1521-4141(200108)31:8<2448::AID-IMMU2448>3.0.CO;2-N, 11500829.
14. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, Visintin I, Rutherford T, Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006, 66:3859-3868. 10.1158/0008-5472.CAN-05-3948, 16585214.
15. Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, Schwartz P, Rutherford T, Azodi M, Mor G. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med 2006, 79:153-163. 1994803, 17940625.
16. Wang AC, Su QB, Wu FX, Zhang XL, Liu PS. Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells. Eur J Clin Invest 2009, 39:157-164. 10.1111/j.1365-2362.2008.02070.x, 19200169.
17. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, Spaczynski M, Whiteside TL. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009, 28:4353-4363. 10.1038/onc.2009.289, 2794996, 19826413.
18. Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001, 81:380-390. 10.1006/gyno.2001.6194, 11371126.
19. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF. Characterization of a cis-Diamminedichloroplatinum(II)-resistant Human Ovarian Cancer Cell Line and Its Use in Evaluation of Platinum Analogues. Cancer Research 1987, 47:414-418.
20. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword?. Br J Cancer 2006, 95:247-252. 10.1038/sj.bjc.6603275, 2360630, 16892041.
21. Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007, 57:93-107. 10.1111/j.1600-0897.2006.00441.x, 17217363.
22. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, Mayer L, Unkeless JC, Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005, 65:5009-5014. 10.1158/0008-5472.CAN-05-0784, 15958541.
23. Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006, 20:1130-1137. 10.1038/sj.leu.2404226, 16628189.
24. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444. 10.1038/nature07205, 18650914.
25. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, Silasi DA, Steffensen KD, Waldstrom M, Visintin I, Mor G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009, 8:158-166. 10.4161/cc.8.1.7533, 3041590, 19158483.
26. Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, Rutherford T, Mor G. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010, 29:3545-3553. 10.1038/onc.2010.111, 2889129, 20400975.
27. d'Adhemar CJ, Gallagher MF, O'Toole S, Murphy C, Smyth PC, Martin C, Sheils O, O'Leary JJ. Functional Expression Analysis of TLR-4 and MYD88 in Epithelial Ovarian Neoplasia. Modern Pathol 2010, 23:239a-239a.
28. Gershenson DM. The Continuum of Serous Ovarian Tumors of Low Malignant Potential and Low-Grade Serous Carcinoma of the Ovary Rare and Uncommon Gynecological Cancers. 2011, Springer Berlin Heidelberg, , Reed N, Green JA, Gershenson DM, Siddiqui N, Connor R.
29. Yang JM, Hung CM, Fu CN, Lee JC, Huang CH, Yang MH, Lin CL, Kao JY, Way TD. Hispidulin sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by AMPK activation leading to Mcl-1 block in translation. J Agric Food Chem 2010, 58:10020-10026. 10.1021/jf102304g, 20734985.
30. Chen SS, Michael A, Butler-Manuel SA. Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals. Discov Med 2012, 13:7-17.
31. Wang TH, Chan YH, Chen CW, Kung WH, Lee YS, Wang ST, Chang TC, Wang HS. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 2006, 25:4857-4866. 10.1038/sj.onc.1209498, 16547493.